Swissmedic
REGULATORY UPDATE
Clinical trials of medicinal products and ATMPs with multiple sponsors
Published: 5/11/2026Detected: 5/11/2026
Summary preview
Clarifies how clinical trials of medicinal products and ATMPs should be structured and governed when multiple sponsors are involved, with attention to accountability for trial operations and compliance.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountclinical
safety
manufacturing
quality
labeling
#Swissmedic
#clinical trials
#multiple sponsors
#ATMP
#pharmacovigilance
Official Source Document Source Verified
Access the original document directly from SWISSMEDIC.
More from Swissmedic
- Extended deadline for publishing officially mandated information materials on the electronic publication platform11/12/2026
- Designer drugs: FDHA brings further psychoactive substances under control11/10/2026
- NAD+ supplements: When lifestyle products have criminal consequences11/9/2026
- Publication eCTD v4.0 Implementation Guide Package v2.011/9/2026
- Save the Date: Clinical Trials Symposium 202711/4/2026